Binding of Tissue Plasminogen Activator to Vascular Grafts

Summary

Tissue plasminogen activator labeled with radioactive iodine (¹²⁵I-tPA) was immobilized on vascular prostheses chemically modified with a thin coating of water-insoluble surfactant, tridodecylmethylammonium chloride (TDM AC). Surfactant- treated Dacron, polytetrafluoroethylene (PTFE), silastic, polyethylene and polyurethane bound appreciable amounts of ¹²⁵I- tPA (5-30 μg ¹²⁵I-tPA/cm²). Upon exposure to human plasma, the amount of ¹²⁵I-tPA bound to the surface shows an initial drop during the first hour of incubation, followed by a slower, roughly exponential release with a t_½ of appoximately 75 hours. Prostheses containing bound tPA show fibrinolytic activity as measured both by lysis of clots formed in vitro, and by hydrolysis of a synthetic polypeptide substrate. Prior to incubation in plasma, tPA bound to a polymer surface has an enzymic activity similar, if not identical to that of the native enzyme in buffered solution. However, exposure to plasma causes a decrease in the fibrinolytic activity of both bound tPA and enzyme released from the surface of the polymer. These data demonstrate that surfactant-treated prostheses can bind tPA, and that these chemically modified devices can act as a slow-release drug delivery system with the potential for reducing prosthesis-induced thromboembolism.

Key words

Tissue plasminogen activator - Thrombolysis - Surfactant - Tridodecylmethylammonium chloride

• References

• 1 Callow AD. Current status of vascular grafts. Surg Clin North Am 1982; 65: 501
• 2 Esquivel CO, Blaisdell FW. Why small caliber vascular grafts fail: A review of clinical and experimental experience and the significance of the interaction of blood at the interface. J Surg Res 1986; 41: 1-15
• 3 Sterpetti AV. et al Seven-year experience with polytetrafluoroethy- lene as above-knee femoropopliteal bypass graft: Is it worthwhile to preserve the autologous saphenous vain. J Vase Surg 1985; 2: 907-912
• 4 Katzen BT, van Breda A. Low-dose streptokinase in the treatment of arterial occlusions. Am J Res 1981; 136: 1171-1178
• 5 Hargrove WC, Baker CF, Berkowitz HD. et al Treatment of acute peripheral arterial and graft thromboses with low-dose streptokinase. Surgery 1983; 93: 981-993
• 6 Sicard GA, Schier JJ, Totty WB. et al Thrombolytic therapy for acute arterial occlusion. J Vase Surg 1985; 2: 65-78
• 7 Van Breda A, Robinson JC, Feldman L. et al Local thrombolysis in the treatment of arterial graft occlusions. J Vase Surg 1984; 1: 103-112
• 8 Hargrove WC, Berkowitz HD, Freiman DB. et al Recanalization of totally occluded femoropopliteal vein grafts with low-dose streptokinase infusion. Surgery 1982; 92: 891-895
• 9 Rijken DC, Collen D. Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J Biol Chem 1981; 256 (13) 7035-7041
• 10 Bachmann F, Kruithof EK O. Tissue plasminogen activator: Clinical and physiological aspects. Sem Thromb Hemostas 1984; 10: 6-17
• 11 Pennica D, Holmes WE, Kohr WJ, Harkins RN, Vehar GA, Ward CA, Bennett WF, Yelverton E, Seeburg PH, Heyneker HL, Goeddel DV, Collen D. Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. Nature 1983; 301: 214
• 12 Graor RA. et al Peripheral artery and bypass graft thrombolysis with recombinant human tissue-type plasminogen activator. J Vase Surg 1986; 1: 115-124
• 13 Sommer HZ, Lipp HI, Jackson LL. Alkylation of amines. A general exhaustive alkylation method for the synthesis of quaternary compounds J Org Chem 1971; 36: 824-829
• 14 Bergsdorf N, Nilsson T, Wallen P. An enzyme linked immunosorbent assay for determination of tissue plasminogen activator applied to patients with thromboembolic disease. Thromb Haemostas 1983; 50: 740-744
• 15 Ranby M, Norrman B, Wallen P. A sensitive assay for tissue plasminogen activator. Thromb Res 1982; 27: 743-749
• 16 Summaria L, Sandesara J, Yang G, Vagher JP, Caprini JA. In vitro comparison of fibrinolytic activity of plasminogen activators using a thrombelastographic method: in vivo evaluation of the B-Chain-Streptokinase complex in the dog model using pretitered doses. Thromb Haemostas 1986; 56: 71-79
• 17 Harvey RA, Tesoriero JV, Greco RS. Noncovalent bonding of penicillin and cefazolin to Dacron. Am J Surg 1984; 147: 205-209
• 18 Gyzander E, Eriksson E, Teger-Nilsson AC. A sensitive assay for tissue plasminogen activator activity in plasma using adsorption on lysine-Sepharose. Thromb Res 1984; 35: 547-558
• 19 Harvey RA, Alcid DV, Greco RS. Antibiotic bonding to polytetrafluoroethylene with tridodecylmethylammonium chloride. Surgery 1982; 92: 504-512
• 20 Kruithof EK O, Ransijn A, Tran-Thang C, Bachmann F. Demonstration of a fast-acting inhibitor of plasminogen activator in human plasma. Blood 1984; 64: 907-913
• 21 Morrison M, Bayse GS, Webster RG. Use of lactoperoxidase catalyzed iodination in immunochemical studies. Immunochemistry 1971; 8: 289-297
• 22 Greco RS, Shue WB, Worosilo SG, Donetz AF, Trooskin SZ, Harvey RA. Prevention of vascular prosthetic infection utilizing an antibiotic bonded Dacron graft. J Vase Surg. (in press)